The Wound Management Innovation Cooperative Research Centre (WMI CRC) has been a catalyst for change in the wound industry since its inception in 2010.
Wrays is an independent IP specialist firm in Australia with significant experience in the recognition, protection and prosecution of intellectual property (IP) rights across a broad range of industries and technologies.
Xerion is dedicated to transforming innovations in life sciences into viable business opportunities that improves quality of life. The company currently has two major business units: a dermatology business and a medical device business.
Zucero Therapeutics is an Australian-based biotechnology company committed to the discovery and development of modified sugar compounds for the treatment of cancer. Pixatimod (PG545) has emerged as Zucero’s first clinical candidate and is classified as an immunomodulatory agent that enhances the host immune system’s ability to suppress cancer.